Nir Barzilai at ARDD2025: Repurposed drugs

Value of the Information & Strength of the Argument

The talk provides valuable insights into the current state of aging biomarkers, particularly proteomics, and the challenges in their development. Barzilai presents data from his own studies, showing that proteomic changes with age are significant and can be influenced by genetics and sex. He argues that while biomarkers are useful, they are not perfect and need to be interpreted cautiously. He also highlights the potential of organ-specific aging to guide personalized interventions. The argumentation is based on his experience and data, but some interpretations are speculative, such as the limited contribution of senescent cells to plasma proteome. He acknowledges the limitations and the need for further research.

Scientific Rigor, Source Quality, Title Accuracy

Barzilai is a well-known researcher, and his talk is based on his own studies and collaborations, which adds credibility. However, he does not provide detailed references or citations during the talk, and the sources are not explicitly mentioned. The title mentions ‘Repurposed drugs’, but the talk is more about biomarkers, which may be slightly misleading. The content is scientifically rigorous but presented in a conversational style, with some humor and personal anecdotes.

The title is broad and the talk focuses on repurposed drugs and biomarkers, but the content is more about proteomic biomarkers and their challenges than about specific drugs.

7/10

Presentation by a leading expert in aging research, based on his own studies and collaborations, but with limited methodological details and some speculative interpretations.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 01:00Introduction and shoutout to HLMS, and mention of his role in the council.
• 02:30Personal anecdote about his epigenetic age and EKG age, and the effect of metformin and fasting.
• 05:00Discussion of proteomic changes with age, volcano plot, and significance of proteins like IL-6 and GDF-15.
• 08:00Comparison of proteomic changes between offspring of centenarians and controls, and sex differences.
• 10:00Collaboration with Judy Campisi on senescent cells and the finding that half of SASP proteins go up and half go down.
• 12:00Importance of insulin/IGF signaling pathway and matrix degradation in aging, and organ-specific aging.
• 15:00Introduction of the FAST initiative to use existing trials to identify biomarkers, and the goal of biomarkers that change within months.
• 18:00Prediction that proteomic tests will be commercially available within two years, and discussion of FDA standardization challenges.
• 20:00Discussion of TAME trial and the need for regulatory acceptance of drugs affecting multiple systems.
• 22:00Q&A: agreement that current proteomic platforms are not yet for clinical practice due to variability.

• ARDD2025 conference — This is the video itself, where the talk was presented.

• Epigenetic clocks — Supports the discussion on epigenetic age and its limitations.
• Proteomics — General background on proteomic technologies.

• No discordant sources found — No conflicting sources were mentioned in the talk.